CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne

Risk of death for people hospitalized after using hallucinogens compared to the general population

Updated

Abstract

Acute care involving hallucinogens was associated with a 2.6-fold increased all-cause mortality risk within 5 years compared to the general population.

  • Out of 11,415,713 people studied, 7,953 (0.07%) had acute care related to hallucinogen use.
  • The absolute risk of death within 5 years for those with hallucinogen-related acute care was 6.1%, compared to 0.6% for the general population.
  • Similar mortality risk increases were observed for individuals without comorbid mental or substance use disorders, with a hazard ratio of 3.25.
  • Elevated risks of death from specific causes included unintentional drug poisoning (HR 2.03), suicide (HR 5.23), respiratory disease (HR 2.46), and cancer (HR 2.88).

Simplified

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Competing interests:: Tyler Kaster reports receiving grants from the Canadian Institutes of Health Research (CIHR), Patient-Centered Outcomes Research Institute, and the AFP Innovation Fund (all paid to institution), and honoraria from the Thunder Bay Regional Health Sciences Centre. Muhammad Ishrat Husain reports receiving grants from CIHR, the University of Toronto, and Compass Pathways Ltd.; consulting fees from Psyched Therapeutics and Mindset Pharma; honoraria from Worksafe BC, Waypoint, the American Society of Clinical Psychopharmacology, and the American College Health Association; and travel support from World Federations of Societies of Biological Psychiatry and the Royal Ottawa Hospital. Dr. Husain has served as vice chair, Pan-American Division, Royal College of Psychiatrists. Dr. Husain holds stock in Mindset Pharma. Joshua Rosenblat reports receiving speaker, consultation, and research fees from AbbVie, iGan, Inagene, Boehringer Ingelheim, Janssen, Braxia Health, Braxia Scientific, Allergan, Lundbeck, Sunovion, and Compass, outside the submitted work. Marco Solmi reports receiving honoraria as speaker from Angelini, AbbVie, and Otsuka, and has participated on advisory boards for Otsuka and AbbVie. No other competing interests were declared.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free